BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AbbVie (ABBV) announced the European
Medicines Agency's Committee for Medicinal Products for Human Use has adopted a
positive opinion recommending the conditional marketing authorization of
epcoritamab, the first T-cell engaging bispecific antibody administered
subcutaneously, as a monotherapy for the treatment of adult patients with
relapsed or refractory follicular lymphoma after two or more prior therapies.
The European Commission decision on this indication is anticipated later in the
current year.

Epcoritamab is being co-developed by AbbVie and Genmab. They will share
commercial responsibilities in the U.S. and Japan, with AbbVie responsible for
further global commercialization.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX